The FY19 Defense Appropriations Act provides $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP)to support innovative and high-impact research into preclinical development of therapeutics for Amyotrophic Lateral Sclerosis.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation.  The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The mission of the ALSRP is to fund innovative preclinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

https://cdmrp.army.mil/funding/alsrp

The following mechanisms have been released:

Therapeutic Development Award – Preproposal due by 3/22/19

• Independent investigators at all academic levels
• Pre-application is required; full application submission is by invitation only
• Supports post-discovery, preclinical development of therapeutics for ALS
• Preliminary data, including identity and purity of an identified bioactive compound(s), are required
• Therapeutically Relevant Marker Option available
• Collaboration with industry is encouraged
• Clinical trials are not allowed

• Maximum funding of $1.0 million for direct costs (plus indirect costs); $1.25 million for direct costs (plus indirect costs) for applications including the Therapeutic Relevant Marker Option
• Maximum period of performance is 2 years

Therapeutic Idea Award – Preproposal due by 3/22/19

• Independent investigators at all academic levels
• Pre-application is required; full application submission is by invitation only
• Supports screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development
• Preliminary data are not required
• Not intended to support projects focusing on the pathophysiology of ALS
• Maximum funding of $500,000 for direct costs (plus indirect costs)
• Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@Ebrap.org

Book mark the CDMRP website:

cdmrp.army.mil

Follow CDMRP on Twitter at:

twitter.com/CDMRP

View CDMRP research results on YouTube:

www.youtube.com/user/CDMRP

Like us on FaceBook:

www.facebook.com/TheCDMRP